Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AN OBSERVATIONAL STUDY OF EFFECTIVENESS AND SAFETY OF THE FIRST LINE NIVOLUMAB PLUS IPILIMUMAB WITH OR WITHOUT CHEMOTHERAPY FOR ADVANCED / RECURRENT NON-SMALL CELL LUNG CANCER IN JAPAN (LIGHT-NING)

Next Previous
Trial Profile

AN OBSERVATIONAL STUDY OF EFFECTIVENESS AND SAFETY OF THE FIRST LINE NIVOLUMAB PLUS IPILIMUMAB WITH OR WITHOUT CHEMOTHERAPY FOR ADVANCED / RECURRENT NON-SMALL CELL LUNG CANCER IN JAPAN (LIGHT-NING)

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Antineoplastics; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms LIGHT-NING
  • Sponsors Bristol-Myers Squibb

Most Recent Events

  • 08 Jul 2025 Planned End Date changed from 30 Apr 2023 to 1 Jun 2026.
  • 08 Jul 2025 Planned primary completion date changed from 30 Apr 2023 to 31 Dec 2025.
  • 08 Jul 2025 Status changed to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top